Recent clinical progress in virus-based therapies for cancer.

Journal Article (Review)

As our knowledge of the molecular basis of cancer expands, viral vectors have been increasingly studied as potential antitumour therapeutic agents. With their ability to invade and replicate within target cells, viruses have been utilised as oncolytic agents to directly lyse tumour cells. Viruses can also deliver their genetic payload into infected cells, allowing for the repair of defective tumour suppressor genes, disruption of oncogenic pathways, and production of cytokines that activate the immune system. Finally, viruses encoding tumour-associated antigens can infect dendritic cells, triggering the development of a tumour-specific immune response. The ability to engineer viruses with high levels of tumour specificity and efficient rates of infection has enhanced the safety profile of these agents, allowing for the development of viable therapeutic options that have been examined in the clinic, either alone or in conjunction with more conventional therapies. This review highlights the principles underlying virus-based therapies for cancer, with an emphasis on recent developments from the clinic.

Full Text

Duke Authors

Cited Authors

  • Woo, CY; Osada, T; Clay, TM; Lyerly, HK; Morse, MA

Published Date

  • November 2006

Published In

Volume / Issue

  • 6 / 11

Start / End Page

  • 1123 - 1134

PubMed ID

  • 17049011

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

Digital Object Identifier (DOI)

  • 10.1517/14712598.6.11.1123

Language

  • eng

Conference Location

  • England